Skip to content

Mannose Glycation of Tumor-Associated Antigens via Intratumoral Maillard Reaction Mediated by a Photothermal Nano-Catalyst for Enhanced Antigen-Presenting Cell Targeting.

Aug 2026 · Small · Vol 22, pp. e75185 · 0 citations · 27 references
Medicine

TL;DR

This work developed mannose-loaded hollow polydopamine nanoparticles (Man@HDA-Pd) and proposed intratumoral-Maillard reaction as a new strategy for the glycation of TAAs, providing valuable insights for the design of in situ tumor vaccines.

Abstract

Immunogenic cell death (ICD) represents a classical pathway for generating personalized anticancer vaccines in situ. However, the poor immunogenicity of released tumor-associated protein antigens (TAAs) remains a major limitation to their therapeutic efficacy. Herein, we developed mannose-loaded hollow polydopamine nanoparticles (Man@HDA-Pd) and proposed intratumoral-Maillard reaction as a new strategy for the glycation of TAAs. The local administration of as-prepared Man@HDA-Pd could efficiently induce ICD effects, leading to the release of abundant TAAs. Furthermore, leveraging the photothermal effect, catalase-like properties of Man@HDA-Pd, these released TAAs undergo mannose-directed glycation via the Maillard reaction, further generating advanced glycation end products (AGEs)-like antigens (denoted as Man-TAAs), thereby endowing them with dendritic cell (DC)-targeting ability and significantly improving their internalization. Concurrently, this man-mediated glycation process is accompanied by elevated reactive oxygen species (ROS), suppressed cell proliferation, and exhibited characteristics of cellular senescence within tumor cells. Additionally, the delivery of Man@HDA-Pd competitively displaces glycans on the immunosuppressive glycoprotein PD-L1 on tumor cell surfaces via a sugar-replacement effect, which would impair its function and inhibit tumor immune escape. Taken together, this work proposes and validates an in situ Maillard-based glycation strategy for enhanced immunotherapy, providing valuable insights for the design of in situ tumor vaccines.

View source

Similar papers

Open access Oct 2026

Supramolecular Pretargeting Lipid Nanoparticles Based on Host-Guest Recognition Potentiate Cancer Immunotherapy by Reprogramming Tumor Microenvironment.

CN-LNPs are employed as a delivery platform to encapsulate a circular RNA encoding IL-2-Fc fusion protein, enabling intratumoral cytokine production to potentiate antitumor immunity and establish a versatile platform that overcomes the intratumoral delivery limitations commonly associated with conventional LNPs system.

Jin-Qun Gan, Yang-Fan Wang, Meng-Yao Li et al. · 0 citations
Open access Sep 2026

Nanozyme‐Assisted Engineered Oncolytic Adenovirus for Improving Intratumoral Immune Deficiency and Enhancing Cancer Immunotherapy

Oncolytic adenovirus (OA) exhibit tumor‐selective tropism, inducing direct oncolysis while simultaneously potentiating host immune responses against malignancies. However, the poor delivery efficiency of the virus targeting tumors and its limited immune activation capacity severely delays the therapeutic effect. This s...

Yu-Qing Lv, Qing-Yuan Wu, Ao-Di Niu et al. · 0 citations
Oct 2026

Internalizing RGD (iRGD)-modified liposomal nanoparticles as a universal antigen-delivering platform for remodeling tumors and enhancing T-cell receptor-engineered T cell immunotherapy.

T cell receptor-engineered T cell (TCR-T) therapy holds promise for solid tumors but faces challenges from insufficient and non-uniform antigen presentation and inefficient T-cell tumor delivery. Current strategies that rely on endogenous tumor antigen expression are often limited by transcriptional silencing or downre...

Hao-Yue Qi, Han-Xi Zhang, Chen-Xu Wang et al. · 0 citations
Oct 2026

A tumor-microenvironment-responsive M1 macrophage-membrane-camouflaged nanoplatform potentiates polyphyllin VII immunotherapy through disrupting the ASNS-mTOR axis and inducing immunogenic cell death for solid tumor treatment.

Polyphyllin VII, a steroidal saponin derived from Paris polyphylla, exhibits potent anti-tumor activity across multiple cancer types. Its clinical application is severely hampered by poor water solubility, non-specific biodistribution, and inherent cytotoxicity to normal tissues. Here, we report a rationally engineered...

Wen-Ya Su, Lu-Yao Tian, Hong-Yan Xu et al. · 0 citations
Oct 2026

Self-assembled ferric-shikonin-quercetin (FSQ) nanoparticles co-delivering R848 enable lactate reduction, ICD induction, and immune modulation in vitro.

To overcome inadequate tumor immunogenicity and the immunosuppressive tumor microenvironment, a self-assembled nanomedicine (R848@FSQ) is developed by coordinating the chemotherapeutic drugs shikonin (SHK) and quercetin (Qu) with Fe3 + to form a metal-phenolic network (MPN), and is simultaneously loaded with the immune...

Xing-Xing Peng, Qi-Wen Chen, Jing Chang et al. · 0 citations
Open access Oct 2026

A biomimetic gas-protein co-delivery nanoplatform targets mitochondrial stress and GSDME activation for glioblastoma immunotherapy

Glioblastoma (GBM) remains one of the most aggressive primary brain malignancies, with the therapeutic efficacy of conventional treatments and cancer immunotherapy being severely hindered by the blood-brain barrier (BBB) and the highly immunosuppressive tumor microenvironment (TME). Although pyroptosis, an inflammatory...

Guang-Yu Ma, Jun-Jie Li, Kai Wang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.